
WHAT IS CLAIMED IS:

1. A compound of formula (II)



(II)

or a pharmaceutically acceptable salt thereof,

wherein,

X^1, X^2, X^3 and X^4 are each independently selected from CH and N;

each occurrence of L is independently selected from $-CH_2NHC(O)-$ and $-CH_2NHS(O)_2-$;

each occurrence of P is independently selected from $-CH_2NHC(O)-$ and $-CH_2NHS(O)_2-$;

each occurrence of Q is independently selected from C_{1-8}alkyl, haloC_{1-8}alkyl, C_{1-8}alkoxyC_{1-8}alkyl, hydroxyC_{1-8}alkyl, carboxylC_{1-8}alkyl, C_{3-12}cycloalkyl, C_{6-14}aryl, 3-15 membered heterocyclyl, and 5-14 membered heteroaryl;

each occurrence of W is independently selected from C_{1-8}alkyl, haloC_{1-8}alkyl, C_{1-8}alkoxyC_{1-8}alkyl, hydroxyC_{1-8}alkyl, carboxylC_{1-8}alkyl, C_{3-12}cycloalkyl, C_{6-14}aryl, 3-15 membered heterocyclyl, and 5-14 membered heteroaryl;

each occurrence of R^1 is independently selected from halogen, cyano, C_{1-8}alkyl, C_{1-8}alkoxy, haloC_{1-8}alkoxyC_{1-8}alkyl, haloC_{1-8}alkyl, C_{3-6}cycloalkyl, 5 membered heterocyclylC_{1-8}alkyl, 5 membered heteroaryl, 5 membered heteroarylC_{1-8}alkyl, and $-C\equiv CR$;

each occurrence of R^2 is independently selected from halogen, cyano, C_{1-8}alkyl, C_{1-8}alkoxy, haloC_{1-8}alkyl, C_{3-6}cycloalkyl, 5 membered heteroaryl, $-C(O)NHR$, $-NHC(O)R$, $-S(O)_2NHR$ and $-C\equiv CR$;

each occurrence of R is independently selected from C_{1-8}alkyl, C_{3-12}cycloalkyl, and C_{6-14}aryl;

'm' is an integer ranging from 0 to 3, both inclusive;

'n' is an integer ranging from 0 to 3, both inclusive;

's' is an integer ranging from 0 to 1, both inclusive; and

't' is an integer ranging from 0 to 1, both inclusive;

with the provisos that (i) 's' and 't' are not '0' simultaneously, and (ii) 'm' and 'n' are not '0' simultaneously.

2. The compound according to claim 1, wherein

each occurrence of R^1 is independently cyano, Cl, F, CHF_2, CF_3, OCH_3, CH_3, (2,2,2-trifluoroethoxy)methyl, cyclopropyl, (pyrrolidin-1-yl)methyl, 4-methylthiophenyl, 5-isopropyl-1,3,4-oxadiazol-2-yl, (3,5-dimethyl-1*H*-pyrazol-1-yl)methyl, 3,3-dimethylbut-1-ynyl, 2-cyclopropylethynyl, (2,5-dichlorophenyl)ethynyl, (4-chloro-2-fluorophenyl)ethynyl, (3-chloro-2-fluorophenyl)ethynyl, (3-(trifluoromethyl)phenyl)ethynyl or (2-chloro-4-(trifluoromethyl)phenyl)ethynyl; and 'n' is 1 or 2.

3. The compound according to claim 1 or 2, wherein


each occurrence of R^2 is independently cyano, Cl, F, CH_3, CF_3, OCH_3, 3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl, cyclopropanecarboxamido, 3,3-dimethylbut-1-ynyl, 2-cyclopropylethynyl, -CONH-[3-(trifluoromethyl)phenyl], -CONH-[3-(difluoromethyl)-4-fluorophenyl] or -CONH-[3-(difluoromethyl)phenyl]; and 'm' is 1 or 2.

4. The compound according to any one of claims 1 to 3, wherein

Q is isopropyl, *tert*-butyl, trifluoromethyl, 1-fluoro-2-methylpropan-2-yl, 1-methoxy-2-methylpropan-2-yl, 1-hydroxy-2-methylpropan-2-yl, cyclopropyl, cyclobutyl, cyclopentyl, 2-fluorophenyl, tetrahydrofuranyl, tetrahydrofuranyl, tetrahydrofuran-2-yl, (S)-tetrahydrofuran-2-yl, (R)-tetrahydrofuran-2-yl, isoxazolyl or 1-methyl-1*H*-imidazole-2-yl; 's' is 1; and 't' is 0.

5. The compound according to any one of claims 1 to 4, wherein W is isopropyl, *tert*-butyl, trifluoromethyl, 1-fluoro-2-methylpropan-2-yl, 1-hydroxy-2-methylpropan-2-yl or cyclopropyl; 't' is 1; and 's' is 0.

6. A compound of the formula (III)



(III)

or a pharmaceutically acceptable salt thereof,

wherein,

X^1, X^2 and X^3 are each independently selected from CH and N;

P is selected from $-CH_2NHC(O)-$ and $-CH_2NHS(O)_2-$;

Q is selected from C_{1-8}alkyl, haloC_{1-8}alkyl, C_{1-8}alkoxyC_{1-8}alkyl, hydroxyC_{1-8}alkyl, carboxylC_{1-8}alkyl, C_{3-12}cycloalkyl, C_{6-14}aryl, 3-15 membered heterocyclyl, and 5-14 membered heteroaryl;

each occurrence of R^1 is independently selected from halogen, cyano, C_{1-8}alkyl, C_{1-8}alkoxy, haloC_{1-8}alkyl and C_{3-6}cycloalkyl;

each occurrence of R^2 is independently selected from halogen, cyano, C_{1-8}alkyl, C_{1-8}alkoxy, haloC_{1-8}alkyl, C_{3-6}cycloalkyl, 5 membered heteroaryl, -C(O)NHR, -NHC(O)R, $-S(O)_2NHR$ and -C≡CR;

each occurrence of R is independently selected from C_{1-8}alkyl, C_{3-12}cycloalkyl, and C_{6-14}aryl;

'm' is an integer ranging from 0 to 3, both inclusive; and

'n' is an integer ranging from 0 to 3, both inclusive; with the proviso that 'm' and 'n' are not '0' simultaneously.

7. The compound according to claim 6, wherein X^1, X^2 and X^3 are CH.

8. The compound according to claim 6 or 7, wherein

each R^1 is, independently, cyano, Cl, F, CHF_2, CF_3, OCH_3, CH_3 or cyclopropyl;

each R^2 is, independently, cyano, Cl, F, CH_3, CF_3 or OCH_3;

P is $-CH_2NHC(O)-$;

'm' is 1 or 2;

'n' is 0, 1 or 2; and

Q is isopropyl, *tert*-butyl, trifluoromethyl, 1-fluoro-2-methylpropan-2-yl, 1-methoxy-2-methylpropan-2-yl, 1-hydroxy-2-methylpropan-2-yl, cyclopropyl, cyclobutyl, cyclopentyl, 2-fluorophenyl, tetrahydrofuranyl, tetrahydrofuranyl, tetrahydrofuran-2-yl, (S)-tetrahydrofuran-2-yl, (R)-tetrahydrofuran-2-yl, isoxazolyl or 1-methyl-1*H*-imidazole-2-yl.

9. A compound selected from

4-(3-(2-Chloro-5-(cyclopropanecarboxamidomethyl)phenyl)-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-1-yl)-2-methoxy-*N*-(3-(trifluoromethyl)phenyl)benzamide;

N-(4-Chloro-3-(1-(4-(3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)-3-methoxyphenyl)-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)benzyl)cyclopropanecarboxamide;

4-(3-(2-Chloro-5-(cyclopropanecarboxamidomethyl)phenyl)-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-1-yl)-*N*-(3-(difluoromethyl)-4-fluorophenyl)-2-methoxybenzamide;

N-(4-Chloro-3-(1-(4-(cyclopropanecarboxamido)-3-methoxyphenyl)-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)benzyl)cyclopropanecarboxamide;

4-(3-(2-Chloro-5-(cyclopropanecarboxamidomethyl)phenyl)-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-1-yl)-*N*-(3-(difluoromethyl)phenyl)-2-methoxybenzamide;

4-(3-(2-Chloro-5-(cyclopropanecarboxamidomethyl)phenyl)-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-1-yl)-*N*-(3-(trifluoromethyl)phenyl)benzamide;

N-(4-Chloro-3-(3-(4-((2,5-dichlorophenyl)ethynyl)-2-fluorophenyl)-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-1-yl)benzyl)cyclopropanecarboxamide;

N-(4-Chloro-3-(3-(4-((4-chloro-2-fluorophenyl)ethynyl)-2-fluorophenyl)-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-1-yl)benzyl)cyclopropanecarboxamide;

N-(4-Chloro-3-(3-(2-fluoro-4-((3-(trifluoromethyl)phenyl)ethynyl)phenyl)-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-1-yl)benzyl)cyclopropanecarboxamide;

N-(4-Chloro-3-(3-(4-((3-chloro-2-fluorophenyl)ethynyl)-2-fluorophenyl)-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-1-yl)benzyl)cyclopropanecarboxamide;

N-(4-Chloro-3-(3-(4-((2-chloro-4-(trifluoromethyl)phenyl)ethynyl)-2-fluorophenyl)-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-1-yl)benzyl)cyclopropanecarboxamide;

N-(4-Chloro-3-(1-(3,4-dichlorophenyl)-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)-2-fluorobenzyl)pivalamide;

N-(4-Chloro-2-fluoro-3-(5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)benzyl)pivalamide;

N-(4-Chloro-3-(1-(2,4-difluorophenyl)-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)-2-fluorobenzyl)pivalamide;

N-(4-Chloro-2-fluoro-3-(1-(4-methoxyphenyl)-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)benzyl)pivalamide;

N-(4-Chloro-2-fluoro-3-(3-(2-fluoro-4-(trifluoromethyl)phenyl)-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-1-yl)benzyl)pivalamide;

N-(4-Chloro-3-(3-(2-chloro-6-fluorophenyl)-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-1-yl)-2-fluorobenzyl)pivalamide;

N-(4-Chloro-3-(1-(4-cyanophenyl)-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)-2-fluorobenzyl)pivalamide;

N-(4-Chloro-3-(3-(4-chloro-2-fluorophenyl)-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-1-yl)-2-fluorobenzyl)pivalamide;

N-(4-Chloro-3-(3-(4-chloro-2-fluorophenyl)-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-1-yl)benzyl)cyclopropanecarboxamide;

N-(4-Chloro-3-(3-(2-fluoro-4-(trifluoromethyl)phenyl)-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-1-yl)benzyl)cyclopropanecarboxamide;

N-(4-Chloro-2-fluoro-3-(5-oxo-3-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1*H*-1,2,4-triazol-1-yl)benzyl)pivalamide;

N-(4-Chloro-2-fluoro-3-(5-oxo-1-(5-(trifluoromethyl)pyridin-2-yl)-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)benzyl)pivalamide;

N-(4-Chloro-2-fluoro-3-(5-oxo-1-(6-(trifluoromethyl)pyridin-3-yl)-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)benzyl)pivalamide;

N-(4-Chloro-3-(1-(4-chlorophenyl)-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)-2-fluorobenzyl)pivalamide;

N-(4-Chloro-3-(5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)benzyl)-2,2,2-trifluoroacetamide;

N-(4-Chloro-3-(5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)benzyl)pivalamide;

(*R*)-*N*-(4-Chloro-3-(5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)benzyl)tetrahydrofuran-2-carboxamide;

N-(4-Chloro-3-(5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)benzyl)cyclopropanesulfonamide;

N-(4-Chloro-3-(5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)benzyl)-2-fluorobenzamide;

N-(4-Chloro-3-(5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)benzyl)isoxazole-5-carboxamide;

N-(3-(1-(4-(Trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)-2,4-dimethylbenzyl)-2,2,2-trifluoroacetamide;

(R)-*N*-(2,4-Dimethyl-3-(5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)benzyl)tetrahydrofuran-2-carboxamide;

N-(3-(1-(4-(Trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)-2,4-dimethylbenzyl)pivalamide;

(S)-*N*-(4-Chloro-3-(1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)-tetrahydrofuran-2-carboxamide;

N-(4-Chloro-3-(1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)-1-methyl-1*H*-imidazole-2-carboxamide;

N-(4-Chloro-2-fluoro-3-(4,5-dihydro-3-(4-(3,3-dimethylbut-1-ynyl)phenyl)-5-oxo-1,2,4-triazol-1-yl)benzyl)pivalamide;

N-(4-Chloro-3-(3-(4-(2-cyclopropylethynyl)phenyl)-4,5-dihydro-5-oxo-1,2,4-triazol-1-yl)-2-fluorobenzyl)pivalamide;

N-(4-Chloro-2-fluoro-5-(1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)-2,2,2-trifluoroacetamide;

N-(4-Chloro-2-fluoro-5-(1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)pivalamide;

N-(4-Chloro-3-(1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)-3-hydroxy-2,2-dimethylpropanamide;

N-(4-Chloro-3-(1-(4-chloro-3-fluorophenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)-2,2,2-trifluoroacetamide;

(R)-*N*-(4-chloro-2-fluoro-5-(5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)benzyl)tetrahydrofuran-2-carboxamide;

N-(4-Chloro-3-(1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)-3-methoxy-2,2-dimethylpropanamide;

N-(4-Chloro-3-(1-(4-chloro-3-fluorophenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)pivalamide;

N-(4-Chloro-5-(1-(4-chlorophenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)-2-fluorobenzyl)pivalamide;

N-(4-Chloro-5-(1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)-2-methoxybenzyl)pivalamide;

N-(4-Chloro-2-fluoro-5-(1-(4-fluoro-3-(trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)pivalamide;

N-(4-Chloro-2-fluoro-5-(1-(6-(trifluoromethyl)pyridin-3-yl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)pivalamide;

N-(2,4-Dichloro-5-(3-(4-(2-cyclopropylethynyl)phenyl)-4,5-dihydro-5-oxo-1,2,4-triazol-1-yl)benzyl)pivalamide;

N-(4-Chloro-5-(1-(3-chloro-4-fluorophenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)-2-fluorobenzyl)pivalamide;

N-(4-Chloro-5-(1-(4-chlorophenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)-2-fluorobenzyl)-2-fluorobenzamide;

N-(4-Chloro-2-fluoro-5-(1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)isobutyramide;

N-(4-Chloro-5-(1-(4-chlorophenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)-2-fluorobenzyl)-3-fluoro-2,2-dimethylpropanamide;

N-(4-Chloro-5-(1-(3-chloro-4-methylphenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)-2-fluorobenzyl)pivalamide;

N-(4-Chloro-5-(3-(4-(2-cyclopropylethynyl)phenyl)-4,5-dihydro-5-oxo-1,2,4-triazol-1-yl)-2-fluorobenzyl)pivalamide;

N-(4-Chloro-2-fluoro-5-(4,5-dihydro-3-(4-(3,3-dimethylbut-1-ynyl)phenyl)-5-oxo-1,2,4-triazol-1-yl)benzyl)pivalamide;

N-(4-Chloro-3-(1-(6-(trifluoromethyl)pyridin-3-yl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)pivalamide;

N-(4-Chloro-3-(1-(3-chloro-4-fluorophenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)pivalamide;

N-(4-Chloro-3-(1-(3-chloro-4-methylphenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)pivalamide;

N-(4-Chloro-3-(3-(4-(2-cyclopropylethynyl)phenyl)-4,5-dihydro-5-oxo-1,2,4-triazol-1-yl)benzyl)pivalamide;

N-(4-Chloro-3-(1-(3-(trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)pivalamide;

N-(4-Chloro-3-(4,5-dihydro-3-(4-(3,3-dimethylbut-1-ynyl)phenyl)-5-oxo-1,2,4-triazol-1-yl)benzyl)isobutyramide;

N-(4-Chloro-3-(1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)isobutyramide;

N-(4-Chloro-3-(3-(4-(trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1,2,4-triazol-1-yl)benzyl)pivalamide;

N-(4-Chloro-3-(3-(3-fluoro-4-(trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1,2,4-triazol-1-yl)benzyl)pivalamide;

N-(4-Chloro-3-(3-(4-chloro-3-(trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1,2,4-triazol-1-yl)benzyl)pivalamide;

N-(4-Chloro-3-(3-(4-fluoro-3-(trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1,2,4-triazol-1-yl)benzyl)pivalamide;

N-(4-Chloro-3-(3-(3-fluoro-4-(3,3-dimethylbut-1-ynyl)phenyl)-4,5-dihydro-5-oxo-1,2,4-triazol-1-yl)benzyl)isobutyramide;

N-(4-Chloro-3-(3-(4-(2-cyclopropylethynyl)-3-fluorophenyl)-4,5-dihydro-5-oxo-1,2,4-triazol-1-yl)benzyl)isobutyramide;

N-(4-Chloro-3-(4,5-dihydro-5-oxo-3-(4-((pyrrolidin-1-yl)methyl)phenyl)-1,2,4-triazol-1-yl)benzyl)pivalamide;

N-(3-(3-(4-((2,2,2-Trifluoroethoxy)methyl)phenyl)-4,5-dihydro-5-oxo-1,2,4-triazol-1-yl)-4-chlorobenzyl)pivalamide;

N-(4-Chloro-3-(4,5-dihydro-3-(4-(5-isopropyl-1,3,4-oxadiazol-2-yl)phenyl)-5-oxo-1,2,4-triazol-1-yl)benzyl)pivalamide;

N-(4-Chloro-3-(1-(4-chloro-3-methylphenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)pivalamide;

N-(4-Chloro-3-(1-(4-chloro-3-methylphenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)isobutyramide;

N-(4-Chloro-3-(1-(3-fluoro-5-(trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)pivalamide;

N-(4-Chloro-3-(1-(4-chloro-3-(trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)pivalamide;

N-(4-Chloro-3-(1-(3-(trifluoromethyl)-4-methylphenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)pivalamide;

N-(4-Chloro-3-(1-(4-(trifluoromethyl)-2-methylphenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)pivalamide;

N-(4-Chloro-3-(1-(3-fluoro-4-(trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)pivalamide;

N-(4-Chloro-3-(1-(3-fluoro-4-(trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)isobutyramide;

N-(4-Chloro-3-{5-oxo-1-[4-(trifluoromethyl)phenyl]-4,5-dihydro-1*H*-1,2,4-triazol-3-yl}benzyl)propane-2-sulfonamide;

N-(4-Chloro-3-(1-(2-fluoro-4-(trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-*1H*-1,2,4-triazol-3-yl)benzyl)pivalamide;

N-(3-(4,5-Dihydro-1-(4-(3,3-dimethylbut-1-ynyl)phenyl)-5-oxo-1*H*-1,2,4-triazol-3-yl)-2,4-dimethylbenzyl)isobutyramide;

N-(3-(1-(4-(2-Cyclopropylethynyl)phenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)-2,4-dimethylbenzyl)pivalamide;

N-(4-Chloro-3-(3-(4-(2-cyclopropylethynyl)-3-fluorophenyl)-4,5-dihydro-5-oxo-1,2,4-triazol-1-yl)benzyl)pivalamide;

N-(4-Chloro-3-(1-(4-(2-cyclopropylethynyl)phenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)pivalamide;

N-(4-Chloro-3-(3-(4-(2-cyclopropylethynyl)-2-fluorophenyl)-4,5-dihydro-5-oxo-1,2,4-triazol-1-yl)benzyl)pivalamide;

N-(3-(1-(4-(2-Cyclopropylethynyl)phenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)-2,4-dimethylbenzyl)-3-fluoro-2,2-dimethylpropanamide;

N-(3-(1-(3-Fluoro-4-(3,3-dimethylbut-1-ynyl)phenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)-2,4-dimethylbenzyl)isobutyramide;

N-(4-Chloro-3-(4,5-dihydro-3-(4-((3,5-dimethyl-1*H*-pyrazol-1-yl)methyl)phenyl)-5-oxo-1,2,4-triazol-1-yl)benzyl)pivalamide;

N-(4-Chloro-2-fluoro-3-(1-(3-fluoro-4-(trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)pivalamide;

N-(4-Chloro-3-(1-(4-chloro-3-(trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)-2-fluorobenzyl)pivalamide;

N-(4-Chloro-3-(1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)-3-fluoro-2,2-dimethylpropanamide;

N-((6-Cyclopropyl-5-(1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)pyridin-3-yl)methyl)pivalamide;

N-(4-Chloro-3-(1-(4-(2-cyclopropylethynyl)-2-fluorophenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)pivalamide;

N-(4-Chloro-3-(5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)benzyl)-2-methylpropane-2-sulfonamide;

N-(4-Chloro-3-(5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)benzyl)cyclobutanecarboxamide;

N-(4-Chloro-3-(5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)benzyl)cyclopentanecarboxamide;

N-((6-(Difluoromethyl)-5-(5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)pyridin-3-yl)methyl)pivalamide;

N-((6-(Difluoromethyl)-5-(5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)pyridin-3-yl)methyl)isobutyramide;

N-((6-(Difluoromethyl)-5-(5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)pyridin-3-yl)methyl)propane-2-sulfonamide;

N-((6-(Difluoromethyl)-5-(5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)pyridin-3-yl)methyl)cyclobutanecarboxamide;


N-(4-Chloro-3-(3-(4-(cyclopropylethynyl)phenyl)-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-1-yl)benzyl)-2,2,2-trifluoroacetamide;

N-(4-Chloro-3-(3-(4-(cyclopropylethynyl)phenyl)-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-1-yl)benzyl)-3-hydroxy-2,2-dimethylpropanamide;

3-Fluoro-*N*-((6-(difluoromethyl)-5-(1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)pyridin-3-yl)methyl)-2,2-dimethylpropanamide;


and pharmaceutically acceptable salts thereof.

10. A compound of the formula




or a pharmaceutically acceptable salt thereof.

11. A compound of the formula



or a pharmaceutically acceptable salt thereof.

12. A compound of formula



or a pharmaceutically acceptable salt thereof.

13. A compound selected from

3-(5-(aminomethyl)-2-chlorophenyl)-1-(4-(trifluoromethyl)phenyl)-1*H*-1,2,4-triazol-5(4*H*)-one;

N-(4-Chloro-3-(5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)benzyl)-2,2,2-trifluoroacetamide;

N-(4-Chloro-3-(4,5-dihydro-3-(4-iodophenyl)-5-oxo-1,2,4-triazol-1-yl)benzyl)pivalamide;

and pharmaceutically acceptable salts thereof.

14. A pharmaceutical composition comprising a compound according to any one of claims 1 to 12 and a pharmaceutically acceptable excipient.

15. The pharmaceutical composition according to claim 14, wherein the pharmaceutically acceptable excipient is a carrier or diluent.


16. The use of a compound according to any one of claims 1 to 12 for the manufacture of a medicament for the prevention or treatment of a mPGES-1 mediated disease, disorder or syndrome in a subject.

17. The use of a compound according to any one of claims 1 to 12 for the manufacture of a medicament for the prevention or treatment of disease, disorder, syndrome or condition selected from the group consisting of inflammation, asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, inflammatory bowel disease, irritable bowel syndrome, pain, inflammatory pain, chronic pain, acute pain, fever, migraine, headache, low back pain, fibromyalgia, myofascial disorders, viral infections, influenza, common cold, herpes zoster, hepatitis C, AIDS, bacterial infections, fungal infections, dysmenorrhea, burns, surgical or dental procedures, malignancies hyperprostaglandin E syndrome, classic Bartter syndrome, synovitis, atherosclerosis, gout, arthritis, osteoarthritis, juvenile arthritis, rheumatoid arthritis, juvenile onset rheumatoid arthritis, rheumatic fever, ankylosing spondylitis, Hodgkin's disease, systemic lupus erythematosus, vasculitis, pancreatitis, nephritis, bursitis, conjunctivitis, iritis, scleritis, uveitis, wound healing, dermatitis, eczema, psoriasis, stroke, diabetes mellitus, cancer, neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis and multiple sclerosis, autoimmune diseases, allergic disorders, rhinitis, ulcers, mild to moderately active ulcerative colitis, familial adenomatous polyposis, coronary heart disease and sarcoidosis.

18. The use according to claim 17, wherein the disease, disorder, syndrome or condition is pain.


19. The use according to claim 17, wherein the disease, disorder, syndrome or condition is chronic pain, acute pain, rheumatoid arthritic pain or osteoarthritic pain.

20. A process for preparing a compound of formula (II)



(II)

or a pharmaceutically acceptable salt thereof, which comprises: reacting a compound of formula (Intermediate-IIA*) with a compound of formula (Intermediate-IIB*) to form a compound of formula (Intermediate-IIC*); and converting the compound of formula (Intermediate-IIC*) to a compound of formula (II):



wherein,

X^1, X^2, X^3 and X^4 are each independently selected from CH and N;

each occurrence of L is independently selected from $-CH_2NHC(O)-$ and $-CH_2NHS(O)_2-$;

each occurrence of P is independently selected from $-CH_2NHC(O)-$ and $-CH_2NHS(O)_2-$;

each occurrence of Q is independently selected from C_{1-8}alkyl, haloC_{1-8}alkyl, C_{1-8}alkoxyC_{1-8}alkyl, hydroxyC_{1-8}alkyl, carboxylC_{1-8}alkyl, C_{3-12}cycloalkyl, C_{6-14}aryl, 3-15 membered heterocyclyl, and 5-14 membered heteroaryl;

each occurrence of W is independently selected from C_{1-8}alkyl, haloC_{1-8}alkyl, C_{1-8}alkoxyC_{1-8}alkyl, hydroxyC_{1-8}alkyl, carboxylC_{1-8}alkyl, C_{3-12}cycloalkyl, C_{6-14}aryl, 3-15 membered heterocyclyl, and 5-14 membered heteroaryl;

each occurrence of R^1 is independently selected from halogen, cyano, C_{1-8}alkyl, C_{1-8}alkoxy, haloC_{1-8}alkoxyC_{1-8}alkyl, haloC_{1-8}alkyl, C_{3-6}cycloalkyl, 5 membered heterocyclylC_{1-8}alkyl, 5 membered heteroaryl, 5 membered heteroarylC_{1-8}alkyl, and -C≡CR;

each occurrence of R^2 is independently selected from halogen, cyano, C_{1-8}alkyl, C_{1-8}alkoxy, haloC_{1-8}alkyl, C_{3-6}cycloalkyl, 5 membered heteroaryl, -C(O)NHR, -NHC(O)R, -$S(O)_2$NHR and -C≡CR;

each occurrence of R is independently selected from C_{1-8}alkyl, C_{3-12}cycloalkyl, and C_{6-14}aryl;

PG^1 represents an amine protecting group;

'm' is an integer ranging from 0 to 3, both inclusive;

'n' is an integer ranging from 0 to 3, both inclusive;

's' is an integer ranging from 0 to 1, both inclusive; and

't' is an integer ranging from 0 to 1, both inclusive;

with the provisos that (i) 's' and 't' are not '0' simultaneously; and (ii) that 'm' and 'n' are not '0' simultaneously.

21. The process according to claim 20, wherein the isocyanate of formula (Intermediate-IIA*) is obtained from the corresponding acid, amide or acid halide derivative.

22. The process according to claim 20, wherein a compound of formula (Intermediate-IIA*) is reacted with a compound of formula (Intermediate-IIB*) in DCM, toluene or EDC.


23. The process according to claim 20, wherein Intermediate-IIC* is not isolated.

24. The process according to claim 20, wherein PG^1 is *tert*-butoxycarbonyl.

25. The process according to claim 20, wherein a compound of formula (Intermediate-IIC*) is converted to compound of formula (II) using an organic acid.

WHAT IS CLAIMED IS:

1. A compound of formula (II)



(II)

or a pharmaceutically acceptable salt thereof,

wherein,

X^1, X^2, X^3 and X^4 are each independently selected from CH and N;

each occurrence of L is independently selected from $-CH_2NHC(O)-$ and $-CH_2NHS(O)_2-$;

each occurrence of P is independently selected from $-CH_2NHC(O)-$ and $-CH_2NHS(O)_2-$;

each occurrence of Q is independently selected from isopropyl, *tert*-butyl, trifluoromethyl, 1-fluoro-2-methylpropan-2-yl, 1-methoxy-2-methylpropan-2-yl, 1-hydroxy-2-methylpropan-2-yl, cyclopropyl, cyclobutyl, cyclopentyl, 2-fluorophenyl, tetrahydrofuranyl, tetrahydrofuranyl, tetrahydrofuran-2-yl, (S)-tetrahydrofuran-2-yl, (R)-tetrahydrofuran-2-yl, isoxazolyl and 1-methyl-1*H*-imidazole-2-yl;

each occurrence of W is independently selected from isopropyl, *tert*-butyl, trifluoromethyl, 1-fluoro-2-methylpropan-2-yl, 1-hydroxy-2-methylpropan-2-yl and cyclopropyl;

each occurrence of R^1 is independently selected from cyano, Cl, F, CHF_2, CF_3, OCH_3, CH_3, (2,2,2-trifluoroethoxy)methyl, cyclopropyl, (pyrrolidin-1-yl)methyl, 5-isopropyl-1,3,4-oxadiazol-2-yl, (3,5-dimethyl-1*H*-pyrazol-1-yl)methyl, 3,3-dimethylbut-1-ynyl, 2-cyclopropylethynyl, (2,5-dichlorophenyl)ethynyl, (4-chloro-2-fluorophenyl)ethynyl, (3-chloro-2-fluorophenyl)ethynyl, (3-(trifluoromethyl)phenyl)ethynyl and (2-chloro-4-(trifluoromethyl)phenyl)ethynyl;

each occurrence of R^2 is independently selected from cyano, Cl, F, CH_3, CF_3, OCH_3, 3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl, cyclopropanecarboxamido, 3,3-dimethylbut-1-ynyl, 2-cyclopropylethynyl, -CONH-[3-(trifluoromethyl)phenyl], -CONH-[3-(difluoromethyl)-4-fluorophenyl] and -CONH-[3-(difluoromethyl)phenyl];

'm' is an integer ranging from 0 to 3, both inclusive;

'n' is an integer ranging from 0 to 3, both inclusive;

's' is an integer ranging from 0 to 1, both inclusive; and

't' is an integer ranging from 0 to 1, both inclusive;

with the provisos that (i) 's' and 't' are not '0' simultaneously, and (ii) 'm' and 'n' are not '0' simultaneously.

2. The compound according to claim 1, wherein

'n' is 1 or 2.

3. The compound according to claim 1 or 2, wherein


'm' is 1 or 2.

4. The compound according to any one of claims 1 to 3, wherein

's' is 1; and 't' is 0.

5. The compound according to any one of claims 1 to 4, wherein 't' is 1; and 's' is 0.

6. A compound of the formula (III)



(III)

or a pharmaceutically acceptable salt thereof,

wherein,

X^1, X^2 and X^3 are each independently selected from CH and N;

P is selected from $-CH_2NHC(O)-$ and $-CH_2NHS(O)_2-$;

Q is selected from isopropyl, *tert*-butyl, trifluoromethyl, 1-fluoro-2-methylpropan-2-yl, 1-methoxy-2-methylpropan-2-yl, 1-hydroxy-2-methylpropan-2-yl, cyclopropyl, cyclobutyl, cyclopentyl, 2-fluorophenyl, tetrahydrofuranyl, tetrahydrofuranyl, tetrahydrofuran-2-yl, (S)-tetrahydrofuran-2-yl, (R)-tetrahydrofuran-2-yl, isoxazolyl and 1-methyl-1*H*-imidazole-2-yl;

each occurrence of R^1 is independently selected from cyano, Cl, F, CHF_2, CF_3, OCH_3, CH_3 and cyclopropyl;

each occurrence of R^2 is independently selected from independently cyano, Cl, F, CH_3, CF_3, OCH_3, 3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl, cyclopropanecarboxamido, 3,3-dimethylbut-1-ynyl, 2-cyclopropylethynyl, -CONH-[3-(trifluoromethyl)phenyl], -CONH-[3-(difluoromethyl)-4-fluorophenyl] and -CONH-[3-(difluoromethyl)phenyl];

'm' is an integer ranging from 0 to 3, both inclusive; and

'n' is an integer ranging from 0 to 3, both inclusive; with the proviso that 'm' and 'n' are not '0' simultaneously.

7. The compound according to claim 6, wherein X^1, X^2 and X^3 are CH.

8. The compound according to claim 6 or 7, wherein

each R^1 is, independently, cyano, Cl, F, CHF_2, CF_3, OCH_3, CH_3 or cyclopropyl;

each R^2 is, independently, cyano, Cl, F, CH_3, CF_3 or OCH_3;

P is $-CH_2NHC(O)-$;

'm' is 1 or 2;

'n' is 0, 1 or 2; and

Q is isopropyl, *tert*-butyl, trifluoromethyl, 1-fluoro-2-methylpropan-2-yl, 1-methoxy-2-methylpropan-2-yl, 1-hydroxy-2-methylpropan-2-yl, cyclopropyl, cyclobutyl, cyclopentyl, 2-fluorophenyl, tetrahydrofuranyl, tetrahydrofuranyl, tetrahydrofuran-2-yl, (S)-tetrahydrofuran-2-yl, (R)-tetrahydrofuran-2-yl, isoxazolyl or 1-methyl-1*H*-imidazole-2-yl.

9. A compound selected from

4-(3-(2-Chloro-5-(cyclopropanecarboxamidomethyl)phenyl)-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-1-yl)-2-methoxy-*N*-(3-(trifluoromethyl)phenyl)benzamide;

N-(4-Chloro-3-(1-(4-(3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)-3-methoxyphenyl)-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)benzyl)cyclopropanecarboxamide;

4-(3-(2-Chloro-5-(cyclopropanecarboxamidomethyl)phenyl)-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-1-yl)-*N*-(3-(difluoromethyl)-4-fluorophenyl)-2-methoxybenzamide;

N-(4-Chloro-3-(1-(4-(cyclopropanecarboxamido)-3-methoxyphenyl)-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)benzyl)cyclopropanecarboxamide;

4-(3-(2-Chloro-5-(cyclopropanecarboxamidomethyl)phenyl)-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-1-yl)-*N*-(3-(difluoromethyl)phenyl)-2-methoxybenzamide;

4-(3-(2-Chloro-5-(cyclopropanecarboxamidomethyl)phenyl)-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-1-yl)-*N*-(3-(trifluoromethyl)phenyl)benzamide;

N-(4-Chloro-3-(3-(4-((2,5-dichlorophenyl)ethynyl)-2-fluorophenyl)-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-1-yl)benzyl)cyclopropanecarboxamide;

N-(4-Chloro-3-(3-(4-((4-chloro-2-fluorophenyl)ethynyl)-2-fluorophenyl)-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-1-yl)benzyl)cyclopropanecarboxamide;

N-(4-Chloro-3-(3-(2-fluoro-4-((3-(trifluoromethyl)phenyl)ethynyl)phenyl)-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-1-yl)benzyl)cyclopropanecarboxamide;

N-(4-Chloro-3-(3-(4-((3-chloro-2-fluorophenyl)ethynyl)-2-fluorophenyl)-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-1-yl)benzyl)cyclopropanecarboxamide;

N-(4-Chloro-3-(3-(4-((2-chloro-4-(trifluoromethyl)phenyl)ethynyl)-2-fluorophenyl)-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-1-yl)benzyl)cyclopropanecarboxamide;

N-(4-Chloro-3-(1-(3,4-dichlorophenyl)-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)-2-fluorobenzyl)pivalamide;

N-(4-Chloro-2-fluoro-3-(5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)benzyl)pivalamide;

N-(4-Chloro-3-(1-(2,4-difluorophenyl)-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)-2-fluorobenzyl)pivalamide;

N-(4-Chloro-2-fluoro-3-(1-(4-methoxyphenyl)-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)benzyl)pivalamide;

N-(4-Chloro-2-fluoro-3-(3-(2-fluoro-4-(trifluoromethyl)phenyl)-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-1-yl)benzyl)pivalamide;

N-(4-Chloro-3-(3-(2-chloro-6-fluorophenyl)-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-1-yl)-2-fluorobenzyl)pivalamide;

N-(4-Chloro-3-(1-(4-cyanophenyl)-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)-2-fluorobenzyl)pivalamide;

N-(4-Chloro-3-(3-(4-chloro-2-fluorophenyl)-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-1-yl)-2-fluorobenzyl)pivalamide;

N-(4-Chloro-3-(3-(4-chloro-2-fluorophenyl)-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-1-yl)benzyl)cyclopropanecarboxamide;

N-(4-Chloro-3-(3-(2-fluoro-4-(trifluoromethyl)phenyl)-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-1-yl)benzyl)cyclopropanecarboxamide;

N-(4-Chloro-2-fluoro-3-(5-oxo-3-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1*H*-1,2,4-triazol-1-yl)benzyl)pivalamide;

N-(4-Chloro-2-fluoro-3-(5-oxo-1-(5-(trifluoromethyl)pyridin-2-yl)-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)benzyl)pivalamide;

N-(4-Chloro-2-fluoro-3-(5-oxo-1-(6-(trifluoromethyl)pyridin-3-yl)-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)benzyl)pivalamide;

N-(4-Chloro-3-(1-(4-chlorophenyl)-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)-2-fluorobenzyl)pivalamide;

N-(4-Chloro-3-(5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)benzyl)-2,2,2-trifluoroacetamide;

N-(4-Chloro-3-(5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)benzyl)pivalamide;

(*R*)-*N*-(4-Chloro-3-(5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)benzyl)tetrahydrofuran-2-carboxamide;

N-(4-Chloro-3-(5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)benzyl)cyclopropanesulfonamide;

N-(4-Chloro-3-(5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)benzyl)-2-fluorobenzamide;

N-(4-Chloro-3-(5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)benzyl)isoxazole-5-carboxamide;

N-(3-(1-(4-(Trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)-2,4-dimethylbenzyl)-2,2,2-trifluoroacetamide;

(R)-*N*-(2,4-Dimethyl-3-(5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)benzyl)tetrahydrofuran-2-carboxamide;

N-(3-(1-(4-(Trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)-2,4-dimethylbenzyl)pivalamide;

(S)-*N*-(4-Chloro-3-(1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)-tetrahydrofuran-2-carboxamide;

N-(4-Chloro-3-(1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)-1-methyl-1*H*-imidazole-2-carboxamide;

N-(4-Chloro-2-fluoro-3-(4,5-dihydro-3-(4-(3,3-dimethylbut-1-ynyl)phenyl)-5-oxo-1,2,4-triazol-1-yl)benzyl)pivalamide;

N-(4-Chloro-3-(3-(4-(2-cyclopropylethynyl)phenyl)-4,5-dihydro-5-oxo-1,2,4-triazol-1-yl)-2-fluorobenzyl)pivalamide;

N-(4-Chloro-2-fluoro-5-(1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)-2,2,2-trifluoroacetamide;

N-(4-Chloro-2-fluoro-5-(1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)pivalamide;

N-(4-Chloro-3-(1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)-3-hydroxy-2,2-dimethylpropanamide;

N-(4-Chloro-3-(1-(4-chloro-3-fluorophenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)-2,2,2-trifluoroacetamide;

(R)-*N*-(4-chloro-2-fluoro-5-(5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)benzyl)tetrahydrofuran-2-carboxamide;

N-(4-Chloro-3-(1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)-3-methoxy-2,2-dimethylpropanamide;

N-(4-Chloro-3-(1-(4-chloro-3-fluorophenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)pivalamide;

N-(4-Chloro-5-(1-(4-chlorophenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)-2-fluorobenzyl)pivalamide;

N-(4-Chloro-5-(1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)-2-methoxybenzyl)pivalamide;

N-(4-Chloro-2-fluoro-5-(1-(4-fluoro-3-(trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)pivalamide;

N-(4-Chloro-2-fluoro-5-(1-(6-(trifluoromethyl)pyridin-3-yl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)pivalamide;

N-(2,4-Dichloro-5-(3-(4-(2-cyclopropylethynyl)phenyl)-4,5-dihydro-5-oxo-1,2,4-triazol-1-yl)benzyl)pivalamide;

N-(4-Chloro-5-(1-(3-chloro-4-fluorophenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)-2-fluorobenzyl)pivalamide;

N-(4-Chloro-5-(1-(4-chlorophenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)-2-fluorobenzyl)-2-fluorobenzamide;

N-(4-Chloro-2-fluoro-5-(1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)isobutyramide;

N-(4-Chloro-5-(1-(4-chlorophenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)-2-fluorobenzyl)-3-fluoro-2,2-dimethylpropanamide;

N-(4-Chloro-5-(1-(3-chloro-4-methylphenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)-2-fluorobenzyl)pivalamide;

N-(4-Chloro-5-(3-(4-(2-cyclopropylethynyl)phenyl)-4,5-dihydro-5-oxo-1,2,4-triazol-1-yl)-2-fluorobenzyl)pivalamide;

N-(4-Chloro-2-fluoro-5-(4,5-dihydro-3-(4-(3,3-dimethylbut-1-ynyl)phenyl)-5-oxo-1,2,4-triazol-1-yl)benzyl)pivalamide;

N-(4-Chloro-3-(1-(6-(trifluoromethyl)pyridin-3-yl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)pivalamide;

N-(4-Chloro-3-(1-(3-chloro-4-fluorophenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)pivalamide;

N-(4-Chloro-3-(1-(3-chloro-4-methylphenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)pivalamide;

N-(4-Chloro-3-(3-(4-(2-cyclopropylethynyl)phenyl)-4,5-dihydro-5-oxo-1,2,4-triazol-1-yl)benzyl)pivalamide;

N-(4-Chloro-3-(1-(3-(trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)pivalamide;

N-(4-Chloro-3-(4,5-dihydro-3-(4-(3,3-dimethylbut-1-ynyl)phenyl)-5-oxo-1,2,4-triazol-1-yl)benzyl)isobutyramide;

N-(4-Chloro-3-(1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)isobutyramide;

N-(4-Chloro-3-(3-(4-(trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1,2,4-triazol-1-yl)benzyl)pivalamide;

N-(4-Chloro-3-(3-(3-fluoro-4-(trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1,2,4-triazol-1-yl)benzyl)pivalamide;

N-(4-Chloro-3-(3-(4-chloro-3-(trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1,2,4-triazol-1-yl)benzyl)pivalamide;

N-(4-Chloro-3-(3-(4-fluoro-3-(trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1,2,4-triazol-1-yl)benzyl)pivalamide;

N-(4-Chloro-3-(3-(3-fluoro-4-(3,3-dimethylbut-1-ynyl)phenyl)-4,5-dihydro-5-oxo-1,2,4-triazol-1-yl)benzyl)isobutyramide;

N-(4-Chloro-3-(3-(4-(2-cyclopropylethynyl)-3-fluorophenyl)-4,5-dihydro-5-oxo-1,2,4-triazol-1-yl)benzyl)isobutyramide;

N-(4-Chloro-3-(4,5-dihydro-5-oxo-3-(4-((pyrrolidin-1-yl)methyl)phenyl)-1,2,4-triazol-1-yl)benzyl)pivalamide;

N-(3-(3-(4-((2,2,2-Trifluoroethoxy)methyl)phenyl)-4,5-dihydro-5-oxo-1,2,4-triazol-1-yl)-4-chlorobenzyl)pivalamide;

N-(4-Chloro-3-(4,5-dihydro-3-(4-(5-isopropyl-1,3,4-oxadiazol-2-yl)phenyl)-5-oxo-1,2,4-triazol-1-yl)benzyl)pivalamide;

N-(4-Chloro-3-(1-(4-chloro-3-methylphenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)pivalamide;

N-(4-Chloro-3-(1-(4-chloro-3-methylphenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)isobutyramide;

N-(4-Chloro-3-(1-(3-fluoro-5-(trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)pivalamide;

N-(4-Chloro-3-(1-(4-chloro-3-(trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)pivalamide;

N-(4-Chloro-3-(1-(3-(trifluoromethyl)-4-methylphenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)pivalamide;

N-(4-Chloro-3-(1-(4-(trifluoromethyl)-2-methylphenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)pivalamide;

N-(4-Chloro-3-(1-(3-fluoro-4-(trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)pivalamide;

N-(4-Chloro-3-(1-(3-fluoro-4-(trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)isobutyramide;

N-(4-Chloro-3-{5-oxo-1-[4-(trifluoromethyl)phenyl]-4,5-dihydro-1*H*-1,2,4-triazol-3-yl}benzyl)propane-2-sulfonamide;

N-(4-Chloro-3-(1-(2-fluoro-4-(trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-*1H*-1,2,4-triazol-3-yl)benzyl)pivalamide;

N-(3-(4,5-Dihydro-1-(4-(3,3-dimethylbut-1-ynyl)phenyl)-5-oxo-1*H*-1,2,4-triazol-3-yl)-2,4-dimethylbenzyl)isobutyramide;

N-(3-(1-(4-(2-Cyclopropylethynyl)phenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)-2,4-dimethylbenzyl)pivalamide;

N-(4-Chloro-3-(3-(4-(2-cyclopropylethynyl)-3-fluorophenyl)-4,5-dihydro-5-oxo-1,2,4-triazol-1-yl)benzyl)pivalamide;

N-(4-Chloro-3-(1-(4-(2-cyclopropylethynyl)phenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)pivalamide;

N-(4-Chloro-3-(3-(4-(2-cyclopropylethynyl)-2-fluorophenyl)-4,5-dihydro-5-oxo-1,2,4-triazol-1-yl)benzyl)pivalamide;

N-(3-(1-(4-(2-Cyclopropylethynyl)phenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)-2,4-dimethylbenzyl)-3-fluoro-2,2-dimethylpropanamide;

N-(3-(1-(3-Fluoro-4-(3,3-dimethylbut-1-ynyl)phenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)-2,4-dimethylbenzyl)isobutyramide;

N-(4-Chloro-3-(4,5-dihydro-3-(4-((3,5-dimethyl-1*H*-pyrazol-1-yl)methyl)phenyl)-5-oxo-1,2,4-triazol-1-yl)benzyl)pivalamide;

N-(4-Chloro-2-fluoro-3-(1-(3-fluoro-4-(trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)pivalamide;

N-(4-Chloro-3-(1-(4-chloro-3-(trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)-2-fluorobenzyl)pivalamide;

N-(4-Chloro-3-(1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)-3-fluoro-2,2-dimethylpropanamide;

N-((6-Cyclopropyl-5-(1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)pyridin-3-yl)methyl)pivalamide;

N-(4-Chloro-3-(1-(4-(2-cyclopropylethynyl)-2-fluorophenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)benzyl)pivalamide;

N-(4-Chloro-3-(5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)benzyl)-2-methylpropane-2-sulfonamide;

N-(4-Chloro-3-(5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)benzyl)cyclobutanecarboxamide;

N-(4-Chloro-3-(5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)benzyl)cyclopentanecarboxamide;

N-((6-(Difluoromethyl)-5-(5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)pyridin-3-yl)methyl)pivalamide;

N-((6-(Difluoromethyl)-5-(5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)pyridin-3-yl)methyl)isobutyramide;

N-((6-(Difluoromethyl)-5-(5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)pyridin-3-yl)methyl)propane-2-sulfonamide;

N-((6-(Difluoromethyl)-5-(5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)pyridin-3-yl)methyl)cyclobutanecarboxamide;


N-(4-Chloro-3-(3-(4-(cyclopropylethynyl)phenyl)-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-1-yl)benzyl)-2,2,2-trifluoroacetamide;

N-(4-Chloro-3-(3-(4-(cyclopropylethynyl)phenyl)-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-1-yl)benzyl)-3-hydroxy-2,2-dimethylpropanamide;

3-Fluoro-*N*-((6-(difluoromethyl)-5-(1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-5-oxo-1*H*-1,2,4-triazol-3-yl)pyridin-3-yl)methyl)-2,2-dimethylpropanamide;


and pharmaceutically acceptable salts thereof.

10. A compound of the formula




or a pharmaceutically acceptable salt thereof.

11. A compound of the formula



or a pharmaceutically acceptable salt thereof.

12. A compound of formula



or a pharmaceutically acceptable salt thereof.

13. A compound selected from

3-(5-(aminomethyl)-2-chlorophenyl)-1-(4-(trifluoromethyl)phenyl)-1*H*-1,2,4-triazol-5(4*H*)-one;

N-(4-Chloro-3-(5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)benzyl)-2,2,2-trifluoroacetamide;

N-(4-Chloro-3-(4,5-dihydro-3-(4-iodophenyl)-5-oxo-1,2,4-triazol-1-yl)benzyl)pivalamide;

and pharmaceutically acceptable salts thereof.

14. A pharmaceutical composition comprising a compound according to any one of claims 1 to 12 and a pharmaceutically acceptable excipient.


15. The pharmaceutical composition according to claim 14, wherein the pharmaceutically acceptable excipient is a carrier or diluent.

16. The use of a compound according to any one of claims 1 to 12 for the manufacture of a medicament for the prevention or treatment of disease, disorder, syndrome or condition selected from the group consisting of inflammation, asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, inflammatory bowel disease, irritable bowel syndrome, pain, inflammatory pain, chronic pain, acute pain, fever, migraine, headache, low back pain, fibromyalgia, myofascial disorders, viral infections, influenza, common cold, herpes zoster, hepatitis C, AIDS, bacterial infections, fungal infections, dysmenorrhea, burns, surgical or dental procedures, malignancies hyperprostaglandin E syndrome, classic Bartter syndrome, synovitis, atherosclerosis, gout, arthritis, osteoarthritis, juvenile arthritis, rheumatoid arthritis, juvenile onset rheumatoid arthritis, rheumatic fever, ankylosing spondylitis, Hodgkin's disease, systemic lupus erythematosus, vasculitis, pancreatitis, nephritis, bursitis, conjunctivitis, iritis, scleritis, uveitis, wound healing, dermatitis, eczema, psoriasis, stroke, diabetes mellitus, cancer, neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis and multiple sclerosis, autoimmune diseases, allergic disorders, rhinitis, ulcers, mild to moderately active ulcerative colitis, familial adenomatous polyposis, coronary heart disease and sarcoidosis.

17. The use according to claim 16, wherein the disease, disorder, syndrome or condition is pain.


18. The use according to claim 16, wherein the disease, disorder, syndrome or condition is chronic pain, acute pain, rheumatoid arthritic pain or osteoarthritic pain.

19. A process for preparing a compound of formula (II)



(II)

or a pharmaceutically acceptable salt thereof, which comprises: reacting a compound of formula (Intermediate-IIA*) with a compound of formula (Intermediate-IIB*) to form a compound of formula (Intermediate-IIC*); and converting the compound of formula (Intermediate-IIC*) to a compound of formula (II):



wherein,

X^1, X^2, X^3 and X^4 are each independently selected from CH and N;

each occurrence of L is independently selected from $-CH_2NHC(O)-$ and $-CH_2NHS(O)_2-$;

each occurrence of P is independently selected from $-CH_2NHC(O)-$ and $-CH_2NHS(O)_2-$;

each occurrence of Q is independently selected from isopropyl, *tert*-butyl, trifluoromethyl, 1-fluoro-2-methylpropan-2-yl, 1-methoxy-2-methylpropan-2-yl, 1-hydroxy-2-methylpropan-2-yl, cyclopropyl, cyclobutyl, cyclopentyl, 2-fluorophenyl, tetrahydrofuranyl, tetrahydrofuranyl, tetrahydrofuran-2-yl, (S)-tetrahydrofuran-2-yl, (R)-tetrahydrofuran-2-yl, isoxazolyl and 1-methyl-1*H*-imidazole-2-yl;

each occurrence of W is independently selected from isopropyl, *tert*-butyl, trifluoromethyl, 1-fluoro-2-methylpropan-2-yl, 1-hydroxy-2-methylpropan-2-yl and cyclopropyl;

each occurrence of R^1 is independently selected from cyano, Cl, F, CHF_2, CF_3, OCH_3, CH_3, (2,2,2-trifluoroethoxy)methyl, cyclopropyl, (pyrrolidin-1-yl)methyl, 5-isopropyl-1,3,4-oxadiazol-2-yl, (3,5-dimethyl-1*H*-pyrazol-1-yl)methyl, 3,3-dimethylbut-1-ynyl, 2-cyclopropylethynyl, (2,5-dichlorophenyl)ethynyl, (4-chloro-2-fluorophenyl)ethynyl, (3-chloro-2-fluorophenyl)ethynyl, (3-(trifluoromethyl)phenyl)ethynyl and (2-chloro-4-(trifluoromethyl)phenyl)ethynyl;

each occurrence of R^2 is independently selected from cyano, Cl, F, CH3, CF3, OCH3, 3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl, cyclopropanecarboxamido, 3,3-dimethylbut-1-ynyl, 2-cyclopropylethynyl, -CONH-[3-(trifluoromethyl)phenyl], -CONH-[3-(difluoromethyl)-4-fluorophenyl] and -CONH-[3-(difluoromethyl)phenyl];

PG^1 represents an amine protecting group;

'm' is an integer ranging from 0 to 3, both inclusive;

'n' is an integer ranging from 0 to 3, both inclusive;

's' is an integer ranging from 0 to 1, both inclusive; and

't' is an integer ranging from 0 to 1, both inclusive;

with the provisos that (i) 's' and 't' are not '0' simultaneously; and (ii) that 'm' and 'n' are not '0' simultaneously.

20. The process according to claim 19, wherein the isocyanate of formula (Intermediate-IIA*) is obtained from the corresponding acid, amide or acid halide derivative.

21. The process according to claim 19, wherein a compound of formula (Intermediate-IIA*) is reacted with a compound of formula (Intermediate-IIB*) in DCM, toluene or EDC.

22. The process according to claim 19, wherein Intermediate-IIC* is not isolated.

23. The process according to claim 19, wherein PG^1 is *tert*-butoxycarbonyl.

24. The process according to claim 19, wherein a compound of formula (Intermediate-IIC*) is converted to compound of formula (II) using an organic acid.